206 related articles for article (PubMed ID: 11276035)
1. A flexible design for multiple armed screening trials.
Sargent DJ; Goldberg RM
Stat Med; 2001 Apr; 20(7):1051-60. PubMed ID: 11276035
[TBL] [Abstract][Full Text] [Related]
2. A group-sequential design for clinical trials with treatment selection.
Stallard N; Friede T
Stat Med; 2008 Dec; 27(29):6209-27. PubMed ID: 18792085
[TBL] [Abstract][Full Text] [Related]
3. A three-outcome design for randomized comparative phase II clinical trials.
Hong S; Wang Y
Stat Med; 2007 Aug; 26(19):3525-34. PubMed ID: 17262879
[TBL] [Abstract][Full Text] [Related]
4. Early selection in a randomized phase II clinical trial.
Steinberg SM; Venzon DJ
Stat Med; 2002 Jun; 21(12):1711-26. PubMed ID: 12111907
[TBL] [Abstract][Full Text] [Related]
5. Targeting population entering phase III trials: a new stratified adaptive phase II design.
Tournoux-Facon C; De Rycke Y; Tubert-Bitter P
Stat Med; 2011 Apr; 30(8):801-11. PubMed ID: 21432875
[TBL] [Abstract][Full Text] [Related]
6. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
Taylor JM; Braun TM; Li Z
Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
[TBL] [Abstract][Full Text] [Related]
7. Implementing a decision-theoretic design in clinical trials: why and how?
Palmer CR; Shahumyan H
Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
[TBL] [Abstract][Full Text] [Related]
8. Adjusting for observable selection bias in block randomized trials.
Ivanova A; Barrier RC; Berger VW
Stat Med; 2005 May; 24(10):1537-46. PubMed ID: 15723426
[TBL] [Abstract][Full Text] [Related]
9. An adaptive group sequential design for phase II/III clinical trials that select a single treatment from several.
Kelly PJ; Stallard N; Todd S
J Biopharm Stat; 2005; 15(4):641-58. PubMed ID: 16022169
[TBL] [Abstract][Full Text] [Related]
10. [Controlled randomized clinical trials].
Jaillon P
Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
[TBL] [Abstract][Full Text] [Related]
11. Group-sequential methods for adaptive seamless phase II/III clinical trials.
Stallard N
J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
[TBL] [Abstract][Full Text] [Related]
12. A model to select regimens for phase III trials for patients with advanced-stage non-small cell lung cancer.
Freidlin B; Breathnach OS; Johnson BE
Clin Cancer Res; 2003 Mar; 9(3):917-22. PubMed ID: 12631588
[TBL] [Abstract][Full Text] [Related]
13. [Introduction to the statistical aspects of planning clinical oncologic phase III studies].
Sylvester R; Minder CE
Urologe A; 1995 Sep; 34(5):367-73. PubMed ID: 7483152
[TBL] [Abstract][Full Text] [Related]
14. A parallel phase I/II clinical trial design for combination therapies.
Huang X; Biswas S; Oki Y; Issa JP; Berry DA
Biometrics; 2007 Jun; 63(2):429-36. PubMed ID: 17688495
[TBL] [Abstract][Full Text] [Related]
15. Dose selection in seamless phase II/III clinical trials based on efficacy and safety.
Kimani PK; Stallard N; Hutton JL
Stat Med; 2009 Mar; 28(6):917-36. PubMed ID: 19152231
[TBL] [Abstract][Full Text] [Related]
16. Seamless Phase II/III combination study through response adaptive randomization.
Wang L; Cui L
J Biopharm Stat; 2007; 17(6):1177-87. PubMed ID: 18027224
[TBL] [Abstract][Full Text] [Related]
17. The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation.
Nixon RM; O'Hagan A; Oakley J; Madan J; Stevens JW; Bansback N; Brennan A
Pharm Stat; 2009; 8(4):371-89. PubMed ID: 19340851
[TBL] [Abstract][Full Text] [Related]
18. An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure.
Taylor DJ; Grobler A; Abdool Karim SS
Clin Trials; 2012 Aug; 9(4):377-84. PubMed ID: 22610168
[TBL] [Abstract][Full Text] [Related]
19. Optimizing randomized phase II trials assessing tumor progression.
Stone A; Wheeler C; Carroll K; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129
[TBL] [Abstract][Full Text] [Related]
20. A seamless phase II/III design with sample-size re-estimation.
Bischoff W; Miller F
J Biopharm Stat; 2009 Jul; 19(4):595-609. PubMed ID: 20183428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
